EDINBURGH, Scotland, Dec. 11,
2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC
BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage
biotechnology company developing platform allogeneic gamma-delta T
cell therapies for cancer and other indications, today announced a
partnership with CareDx, Inc. (NASDAQ: CDNA) The Transplant
Company™ who will perform pharmacokinetic analysis using its
AlloCell™ solution in the ACHIEVE clinical trial.
The ACHIEVE clinical trial is an adaptive, open-label, phase II
study designed to evaluate the efficacy and effectiveness of
TCB008, an allogeneic gamma delta T cell therapy for patients with
Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS).
CareDx is a leading precision medicine company focused on
discovering, developing, and commercializing healthcare solutions
for transplant patients and caregivers. CareDx's AlloCell test, a
sensitive solution for pharmacokinetic monitoring of allogeneic
immune and stem cell therapies, will be used to evaluate the
expansion and persistence of TCB008 in patients enrolled in the
ACHIEVE trial.
It is expected that these expansion and persistence data will
provide an understanding of the duration and effect of TCB008 Gamma
Delta T-Cells in reconstituting the immune system of acute myeloid
leukemia patients enrolled in the ACHIEVE trial.
"Our partnership with CareDx is a significant milestone," said
Alison Bracchi, Executive Vice
President of Clinical Operations at TC BioPharm. "The collaboration
is pivotal to the development and optimization of TCB008 as a
therapy for acute myeloid leukemia and other blood cancers."
"We are thrilled to continue to progress the science of
allogeneic cell therapy for patients battling acute myeloid
leukemia," said Marica Grskovic,
PhD, CareDx Chief Strategy Officer. "This partnership builds upon
our growth strategy to expand into hematology oncology with
pharmacokinetic and monitoring assays for patients undergoing cell
therapy."
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of
gamma-delta T cell therapies for the treatment of cancer with human
efficacy data in acute myeloid leukemia. Gamma-delta T cells are
naturally occurring immune cells that embody properties of both the
innate and adaptive immune systems and can intrinsically
differentiate between healthy and diseased tissue.
TC BioPharm is the leader in developing gamma-delta T cell
therapies, and the first company to conduct phase II/pivotal
clinical studies in oncology. The Company is conducting two
investigator-initiated clinical trials for its unmodified
gamma-delta T cell product line - Phase 2b/3 pivotal trial in treatment of acute myeloid
leukemia using the Company's proprietary allogeneic CryoTC
technology to provide frozen product to clinics worldwide.
Forward-Looking Statements for TC BioPharm
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this Current Report on Form 8-K
that do not relate to matters of historical fact should be
considered forward-looking statements, including without limitation
statements regarding the Company's intent or ability to affect any
budget savings or execute on any M&A or capital raising
strategy. These statements are based on management's current
assumptions and are neither promises nor guarantees, but involve
known and unknown risks, uncertainties and other important factors
that may cause the Company's actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. For other important factors that could
cause actual results to differ materially from the forward-looking
statements in this Current Report on Form 8-K, please see the risks
and uncertainties identified under the heading "Risk Factors" in
our Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed
with the SEC, all of which is available on the Company's Investor
Relations website at www.tcbiopharm.com and on the SEC website at
www.sec.gov. All forward-looking statements reflect the Company's
beliefs and assumptions only as of the date of this Current Report
on Form 8-K. The Company undertakes no obligation to update
forward-looking statements to reflect future events or
circumstances.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tcbp-partners-with-caredx-to-support-achieve-clinical-trial-using-allocell-for-pharmacokinetic-monitoring-of-allogeneic-cell-therapy-302327782.html
SOURCE TC BioPharm